The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis.


Journal

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
ISSN: 1551-5044
Titre abrégé: J Histochem Cytochem
Pays: United States
ID NLM: 9815334

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 12 1 2019
medline: 25 4 2020
entrez: 12 1 2019
Statut: ppublish

Résumé

Chemokines and their receptors have been proposed to play important roles in tumor progression and metastasis. To investigate their roles in the progression of primary and metastatic malignant liver tumors and their prognosis, we compared expression profiles of CXCL12/CXCR4, CCL20/CCR6, and CCL21/CCR7 in hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM). Immunohistochemistry was used to analyze the expression levels of the chemokine/chemokine receptor pairs in 29 HCC and 11 CRLM specimens and adjacent non-cancerous tissues, and correlations with clinicopathological variables and overall survival were determined. CCL20/CCR6 expression was higher in HCC than in adjacent non-cancerous tissues. High CCR6 expression in HCC was negatively associated with 5-year survival rate and was an independent prognostic factor for overall survival of HCC patients, whereas differences were not observed between CRLM and adjacent tissues. Furthermore, significantly higher expression of CCL21/CCR7 was found in CRLM than in HCC. In summary, the CCL20/CCR6 axis was elevated in HCC but not in CRLM, whereas the CCL21/CCR7 axis was elevated in CRLM but not in HCC.

Identifiants

pubmed: 30633620
doi: 10.1369/0022155418824274
pmc: PMC6495487
doi:

Substances chimiques

Biomarkers, Tumor 0
CCL20 protein, human 0
CCL21 protein, human 0
CCR6 protein, human 0
CCR7 protein, human 0
Chemokine CCL20 0
Chemokine CCL21 0
Chemokines 0
Receptors, CCR6 0
Receptors, CCR7 0
Receptors, Chemokine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-308

Références

Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Int J Cancer. 2001 Mar 1;91(5):597-606
pubmed: 11267967
Blood. 2002 Sep 1;100(5):1551-8
pubmed: 12176869
Cancer Biother Radiopharm. 2005 Aug;20(4):401-9
pubmed: 16114988
Tumour Biol. 2006;27(3):166-74
pubmed: 16641550
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):161-8
pubmed: 16706828
Scand J Immunol. 2006 Jun;63(6):468-77
pubmed: 16764701
Oncol Rep. 2006 Jul;16(1):109-13
pubmed: 16786131
Br J Cancer. 2006 Jul 17;95(2):210-7
pubmed: 16819541
World J Gastroenterol. 2006 Nov 7;12(41):6627-33
pubmed: 17075975
Mol Cancer Res. 2007 Jan;5(1):21-33
pubmed: 17259344
J Exp Clin Cancer Res. 2007 Dec;26(4):527-33
pubmed: 18365549
Cell Mol Immunol. 2008 Oct;5(5):373-8
pubmed: 18954561
World J Gastroenterol. 2010 Apr 21;16(15):1832-6
pubmed: 20397259
Dig Liver Dis. 2011 Jan;43(1):40-7
pubmed: 20609636
Tumour Biol. 2011 Feb;32(1):189-96
pubmed: 20865359
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S339-46
pubmed: 21584832
PLoS One. 2011;6(9):e24671
pubmed: 21935436
J Gastrointest Surg. 2012 Apr;16(4):828-36
pubmed: 22072303
Scand J Immunol. 2013 Sep;78(3):298-305
pubmed: 23790181
J Surg Oncol. 2014 Aug;110(2):151-5
pubmed: 24634224
Int J Mol Sci. 2014 Apr 16;15(4):6441-52
pubmed: 24743888
Gastroenterology. 2014 Sep;147(3):577-594.e1
pubmed: 25066692
Hepatology. 2015 Mar;61(3):1066-79
pubmed: 25066777
World J Gastroenterol. 2015 Jan 14;21(2):475-83
pubmed: 25593462
World J Hepatol. 2015 Jun 8;7(10):1390-402
pubmed: 26052384
Drug Des Devel Ther. 2015 Jul 15;9:3625-33
pubmed: 26203228
World J Hepatol. 2015 Aug 18;7(17):2080-90
pubmed: 26301050
Scand J Immunol. 2016 Jan;83(1):33-7
pubmed: 26331965
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
APMIS. 2018 May;126(5):359-370
pubmed: 29676815

Auteurs

Xiaolei Jiao (X)

Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Key Laboratory of Artificial Cells, Tianjin Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China.

Guiming Shu (G)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Hui Liu (H)

Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Key Laboratory of Artificial Cells, Tianjin Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China.

Qin Zhang (Q)

Department of Pathology, Tianjin Third Central Hospital, Tianjin, China.

Zhe Ma (Z)

Department of Pathology, Tianjin Third Central Hospital, Tianjin, China.

Chaoyi Ren (C)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Hongsheng Guo (H)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Jingxiang Shi (J)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Junguo Liu (J)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Chuanshan Zhang (C)

Department of Pathology, Tianjin Third Central Hospital, Tianjin, China.

Yijun Wang (Y)

Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.

Yingtang Gao (Y)

Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Key Laboratory of Artificial Cells, Tianjin Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH